These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15370011)

  • 61. Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers.
    Fischer A; Jönsson M; Hjelmström P
    Drug Dev Ind Pharm; 2015 Jan; 41(1):79-84. PubMed ID: 24099551
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacokinetics of the combination tablet of buprenorphine and naloxone.
    Chiang CN; Hawks RL
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S39-47. PubMed ID: 12738349
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment.
    Nielsen S; Dietze P; Lee N; Dunlop A; Taylor D
    Addiction; 2007 Apr; 102(4):616-22. PubMed ID: 17286641
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Buprenorphine-naloxone buccal soluble film for the treatment of opioid dependence: current update.
    Soyka M
    Expert Opin Drug Deliv; 2015 Feb; 12(2):339-47. PubMed ID: 25156759
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Two-year Experience with Buprenorphine-naloxone (Suboxone) for Maintenance Treatment of Opioid Dependence Within a Private Practice Setting.
    Finch JW; Kamien JB; Amass L
    J Addict Med; 2007 Jun; 1(2):104-10. PubMed ID: 21768942
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Buprenorphine, buprenorphine/naloxone and methadone maintenance: a cost-effectiveness analysis.
    Doran CM
    Expert Rev Pharmacoecon Outcomes Res; 2005 Oct; 5(5):583-91. PubMed ID: 19807585
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations.
    Larance B; Dietze P; Ali R; Lintzeris N; White N; Jenkinson R; Degenhardt L
    Drug Alcohol Rev; 2015 Nov; 34(6):603-10. PubMed ID: 25950232
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review.
    Bell J; Mutch C
    Drug Alcohol Rev; 2006 Mar; 25(2):167-71. PubMed ID: 16627307
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Subjective effects of additional doses of buprenorphine in patients on buprenorphine maintenance.
    Singhal A; Tripathi BM; Pal HR; Jena R; Jain R
    Addict Behav; 2007 Feb; 32(2):320-31. PubMed ID: 16814937
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.
    Ciraulo DA; Hitzemann RJ; Somoza E; Knapp CM; Rotrosen J; Sarid-Segal O; Ciraulo AM; Greenblatt DJ; Chiang CN
    J Clin Pharmacol; 2006 Feb; 46(2):179-92. PubMed ID: 16432270
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone).
    Simojoki K; Vorma H; Alho H
    Subst Abuse Treat Prev Policy; 2008 Jun; 3():16. PubMed ID: 18559110
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R; Kayser H; Sittl R
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: a pilot randomized clinical trial.
    Chawarski MC; Mazlan M; Schottenfeld RS
    Drug Alcohol Depend; 2008 Apr; 94(1-3):281-4. PubMed ID: 18164145
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Is there enough naloxone to deter the diversion? Effect of concurrent administration of intravenous naloxone on opioid agonist effects of intravenous buprenorphine: A randomised, double-blind, within-subject, crossover study among opioid-dependent subjects.
    Dhagudu NK; Ambekar A; Agrawal A; Rao R; Mishra AK; Jain R; Singh S
    Drug Alcohol Rev; 2020 Jul; 39(5):595-603. PubMed ID: 32162420
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.
    Middleton LS; Nuzzo PA; Lofwall MR; Moody DE; Walsh SL
    Addiction; 2011 Aug; 106(8):1460-73. PubMed ID: 21395892
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A naturalistic comparison of the effectiveness of methadone and two sublingual formulations of buprenorphine on maintenance treatment outcomes: findings from a retrospective multisite study.
    Proctor SL; Copeland AL; Kopak AM; Herschman PL; Polukhina N
    Exp Clin Psychopharmacol; 2014 Oct; 22(5):424-33. PubMed ID: 25069011
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Methods and motivations for buprenorphine diversion from public opioid substitution treatment clinics.
    Winstock AR; Lea T; Jackson AP
    J Addict Dis; 2009; 28(1):57-63. PubMed ID: 19197596
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The acceptability, safety, and tolerability of methadone/naloxone in a 50:1 ratio.
    Bell J; Shearer J; Ryan A; Graham R; Korompay K; Rizzo S; Sindhusake D; Somogyi AA
    Exp Clin Psychopharmacol; 2009 Jun; 17(3):146-53. PubMed ID: 19586229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.